FindTrial
Sign In

The evaluation of the efficacy of DIMENSION (Diagnosis Method of Neuronal Dysfunction) to diagnosis of Alzheimer's disease

The evaluation of the efficacy of DIMENSION (Diagnosis Method of Neuronal Dysfunction) to diagnosis of Alzheimer's disease - Usefulness to Alzheimer's disease diagnosis of DIMENSION (Diagnosis Method of Neuronal Dysfunction)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000014224
Enrollment
100
Registered
2014-06-11
Start date
2014-06-11
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dementia

Interventions

The electroencephalography for 5 to 15 minutes, Collection of cerebrospinal fluid, SPECT, Neuropsychological test

Sponsors

Department of Biological Regulation, School of Health Science, Faculty of Medicine, Tottori University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1)Alzheimer's disease, non-Alzheimer's disease neuropathy (2)Patients who obtained informed consent.

Exclusion criteria

Exclusion criteria: Patients other than the above

Design outcomes

Primary

MeasureTime frame
DIMENSION analysis(D alpha,D sigma), cerebrospinal fluid biomarker(amyloid beta protein, phosphorylated tau protein), cerebral blood flow, Mini-Mental State Examination(MMSE), Hasegawa's Dementia Scale Revised(HDS-R), Alzheimer's Disease Assessment Scale (ADAS)—

Countries

Japan

Contacts

Public ContactKatsuya Urakami

School of Health Science, Faculty of Medicine, Tottori University Department of Biological Regulation

kurakami@med.tottori-u.ac.jp0859-38-6354

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026